Navigation Links
MaxCyte Debuts the STX Scalable Transfection System at the A/C/T Assays & Cellular Targets Meeting

GAITHERSBURG, Md., Sept. 23 /PRNewswire/ -- MaxCyte, Inc., the pioneer in scalable, high performance cell loading systems, announces that they will be conducting a Product Demonstration of the MaxCyte STX Scalable Transfection System on Thursday, September 25, 2008, at 10:00AM PDT, at the A/C/T Assays & Cellular Targets Conference in San Diego, California.

According to Dr. Madhusudan Peshwa, Vice President of Research and Development at MaxCyte, "The MaxCyte STX Scalable Transfection System can be used to transfect primary cells, cell lines, and stem cells with a range of molecules, including DNA plasmids, different types of RNA, proteins, etc., with very high efficiency. Over ten billion cells can be transfected in 30 minutes. This scale and capability can greatly improve the productivity of drug discovery laboratories. We are pleased to have the opportunity to demonstrate this technology at the A/C/T Meeting."

"We are very excited that the pharmaceutical industry views the MaxCyte STX technology as key to reducing drug discovery bottlenecks," says MaxCyte President and CEO, Doug Doerfler. "The MaxCyte STX can produce a large number of transfected cells in minutes compared to current time-consuming and inconsistent methods. Cells modified using the MaxCyte STX can be used on the research scale and in high-throughput screening assays. The faster you can get to the assay, the more compounds you can screen for biological activity, and the greater your likelihood of finding a successful drug candidate."

After the Product Demonstration, MaxCyte scientists will be available at the A/C/T Meeting to answer any technical questions relative to the performance and operation of the MaxCyte STX Scalable Transfection System.

About MaxCyte

MaxCyte specializes in cell modification technologies to enable the discovery, development, manufacturing, and delivery of innovative therapeutic products. Drawing on its cell therapy expertise, MaxCyte has designed the MaxCyte STX Transfection System expressly for rapid, scalable, and reagent-free cell transfection for cell based assays, preclinical protein production, and other cell-based applications.

For more information,

SOURCE MaxCyte, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MaxCyte to Present at BIO-Europe Spring 2008 Conference
2. Binex and MaxCyte Collaborate on Cancer Immunotherapy Research
3. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
4. 2008 National Ergonomics Conference Schedule Announced, Features Four New Tracks of Programming and Focus on Corporate Sustainability and Productivity; Most Product Debuts in Expos 14-Year History
5. National Stem Cell Holding, Inc. (Ticker NHGI) Subsidiary Proteoderm, Inc. Debuts Cosmoceutical Line at the 2008 World Congress on Anti-Aging Medicine
6. Polymathic Analytical Labs Debuts at World's Largest Medical Design & Manufacturing Exhibition
7. PAL Health Technologies Debuts Xtremityscan System at Western Podiatric Medical Congress
8. Bluestar Silicones Debuts New Soft Elastomers at Medical Device & Manufacturing East Expo
9. International Center for Adult Stem Cell Education Debuts at Spinal Cord Injury Symposium in Greece
10. First-Ever Cancer and Careers Seminar Debuts in Orange County
11. Organogenesis Debuts Educational Campaign for Sufferers of Chronic Leg and Foot Ulcers
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... HART ), a biotechnology company developing bioengineered organ implants ... McGorry will present at the LD Micro "Main ... 2:30 p.m. PT. The presentation will be webcast live ... Management will also be available at the conference for ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and ... early in their initial angel funding process. Now, they are paying it forward ... make early stage investments in the microbiome space. In this, they join ...
Breaking Biology Technology:
(Date:11/17/2015)... LIVERMORE, Calif. , Nov. 17, 2015  Vigilant ... has joined its Board of Directors. ... Vigilant,s Board after recently retiring from the partnership at ... owning 107 companies with over $140 Billion in revenue.  ... performance improvement across all the TPG companies, from 1997 ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever that ... muscular dystrophy (DMD) has provided a new lead for ... Hospital, the Broad Institute of MIT and Harvard and ... . Cell, pinpoints a ... "escape" the disease,s effects. The Boston Children,s lab of ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
Breaking Biology News(10 mins):